MCID: CHL061
MIFTS: 50

Childhood Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Childhood Leukemia

MalaCards integrated aliases for Childhood Leukemia:

Name: Childhood Leukemia 12 42 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:7757
NCIt 49 C4989
UMLS 71 C1332977

Summaries for Childhood Leukemia

MedlinePlus : 42 Leukemia is cancer of the white blood cells. It is the most common type of childhood cancer. Your blood cells form in your bone marrow. White blood cells help your body fight infection. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. Leukemia can develop quickly or slowly. Acute leukemia is a fast growing type while chronic leukemia grows slowly. Children with leukemia usually have one of the acute types. Symptoms include Infections Fever Loss of appetite Tiredness Easy bruising or bleeding Swollen lymph nodes Night sweats Shortness of breath Pain in the bones or joints Risk factors for childhood leukemia include having a brother or sister with leukemia, having certain genetic disorders and having had radiation or chemotherapy. Treatment often cures childhood leukemia. Treatment options include chemotherapy, other drug therapy and radiation. In some cases bone marrow and blood stem cell transplantation might help. NIH: National Cancer Institute

MalaCards based summary : Childhood Leukemia is related to childhood acute lymphocytic leukemia and lymphocytic leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Childhood Leukemia is TCF3 (Transcription Factor 3), and among its related pathways/superpathways are Pathways in cancer and Endometrial cancer. The drugs Chlorambucil and alemtuzumab have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Reduced mammosphere formation

Disease Ontology : 12 A leukemia that occurs in children.

Wikipedia : 74 Childhood leukemia is leukemia that occurs in a child and is a type of childhood cancer. Childhood... more...

Related Diseases for Childhood Leukemia

Diseases related to Childhood Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 324)
# Related Disease Score Top Affiliating Genes
1 childhood acute lymphocytic leukemia 31.4 TCF3 PBX1 MTHFR ETV6 ARID5B
2 lymphocytic leukemia 31.2 TP53 RUNX1 PTPN11 KMT2A ETV6 BCR
3 acute leukemia 30.6 TCF3 RUNX1 MTHFR MLLT3 MLLT1 KMT2A
4 testicular leukemia 30.6 ETV6 ABL1
5 precursor t-cell acute lymphoblastic leukemia 30.4 KMT2A ETV6 CDKN2A BCR ABL1
6 myeloid leukemia 30.4 TP53 RUNX1 PTPN11 KMT2A ETV6 BCR
7 pancytopenia 30.3 TP53 RUNX1 KMT2A DHFR
8 juvenile myelomonocytic leukemia 30.2 TP53 RUNX1 PTPN11 KMT2A
9 lymphoma, non-hodgkin, familial 30.1 TP53 MDM2 KMT2A ETV6 CDKN2A BCR
10 monocytic leukemia 30.0 RUNX1 MLLT3 KMT2A
11 familial retinoblastoma 30.0 TP53 MDM2 CDKN2A
12 acute t cell leukemia 30.0 TP53 TCF3 CDKN2A ABL1
13 leiomyosarcoma 29.9 TP53 MDM2 CDKN2A
14 leukemia, chronic myeloid 29.9 TP53 RUNX1 PTPN11 KMT2A ETV6 BCR
15 methotrexate toxicity 29.9 TYMS SLC19A1 MTHFR DHFR
16 brain cancer 29.8 TP53 RUNX1 PTPN11 MDM2 ETV6 CYP1A1
17 leukemia, acute lymphoblastic 3 29.8 TP53 TCF3 RUNX1 PBX1 KMT2A ETV6
18 leukemia 29.7 TP53 TCF3 RUNX1 PTPN11 PBX1 MTHFR
19 glioma susceptibility 1 29.7 TP53 PTPN11 MDM2 CDKN2A
20 myeloproliferative neoplasm 29.5 RUNX1 PTPN11 MDM2 KMT2A ETV6 BCR
21 hematologic cancer 29.4 TP53 RUNX1 PTPN11 KMT2A ETV6 BCR
22 retinoblastoma 29.4 TYMS TP53 MDM2 DHFR CDKN2A ABL1
23 myelodysplastic syndrome 29.4 TP53 RUNX1 PTPN11 MDM2 KMT2A ETV6
24 leukemia, acute myeloid 29.4 TP53 TCF3 RUNX1 PTPN11 PBX1 MLLT3
25 leukemia, chronic lymphocytic 29.2 TP53 PTPN11 MDM2 KMT2A CDKN2A BCR
26 leukemia, acute lymphoblastic 28.9 TYMS TCF3 SLC19A1 RUNX1 PTPN11 PBX1
27 pediatric t-cell leukemia 11.2
28 ring chromosome 21 10.6 KMT2A ETV6
29 hemifacial spasm 10.6 TYMS MTHFR
30 ring chromosome 7 10.6 TP53 MDM2
31 tafro syndrome 10.6 TCF3 RUNX1
32 actinic cheilitis 10.6 TP53 MDM2
33 bone giant cell sarcoma 10.6 TP53 MDM2
34 maxillary sinus adenocarcinoma 10.5 TP53 MDM2
35 parotid gland cancer 10.5 TP53 ETV6
36 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.5 RUNX1 KMT2A ETV6
37 acute myeloid leukemia with t(9;11)(p22;q23) 10.5 MLLT3 KMT2A
38 methotrexate dose selection 10.5 SLC19A1 MTHFR
39 mediastinum liposarcoma 10.5 MDM2 CDKN2A
40 differentiated thyroid carcinoma 10.5 TP53 MTHFR ETV6
41 soft tissue sarcoma 10.5 TP53 MDM2
42 vulvar intraepithelial neoplasia 10.5 TP53 CDKN2A
43 philadelphia-negative chronic myeloid leukemia 10.5 BCR ABL1
44 heart leiomyosarcoma 10.5 MDM2 CDKN2A
45 ovarian seromucinous carcinoma 10.5 TP53 CDKN2A
46 oral submucous fibrosis 10.5 TP53 MDM2 CYP1A1
47 spitz nevus 10.5 TP53 CDKN2A
48 atypical chronic myeloid leukemia 10.5 RUNX1 ETV6 ABL1
49 mediastinum sarcoma 10.5 MDM2 CDKN2A
50 inflammatory liposarcoma 10.5 MDM2 CDKN2A

Graphical network of the top 20 diseases related to Childhood Leukemia:



Diseases related to Childhood Leukemia

Symptoms & Phenotypes for Childhood Leukemia

UMLS symptoms related to Childhood Leukemia:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Childhood Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ABL1 DHFR MDM2 PBX1 TP53 TYMS
2 Reduced mammosphere formation GR00396-S 9.17 ETV6 KMT2A MDM2 PTPN11 RUNX1 TCF3

MGI Mouse Phenotypes related to Childhood Leukemia:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.49 ABL1 ARID5B BCR CDKN2A CYP1A1 DHFR
2 hematopoietic system MP:0005397 10.48 ABL1 ARID5B BCR CDKN2A CYP1A1 DHFR
3 homeostasis/metabolism MP:0005376 10.47 ABL1 ARID5B BCR CDKN2A CYP1A1 DHFR
4 immune system MP:0005387 10.45 ABL1 ARID5B BCR CDKN2A CYP1A1 DHFR
5 cellular MP:0005384 10.41 ABL1 ARID5B BCR CDKN2A DHFR ETV6
6 mortality/aging MP:0010768 10.41 ABL1 ARID5B BCR CDKN2A CYP1A1 DHFR
7 embryo MP:0005380 10.39 ABL1 CDKN2A DHFR ETV6 KMT2A MDM2
8 cardiovascular system MP:0005385 10.35 ABL1 CDKN2A CYP1A1 DHFR ETV6 KMT2A
9 endocrine/exocrine gland MP:0005379 10.35 ABL1 ARID5B CDKN2A CYP1A1 ETV6 MDM2
10 liver/biliary system MP:0005370 10.35 ABL1 BCR CDKN2A CYP1A1 DHFR KMT2A
11 digestive/alimentary MP:0005381 10.28 ABL1 ARID5B BCR CDKN2A ETV6 MDM2
12 integument MP:0010771 10.25 CDKN2A DHFR ETV6 KMT2A MDM2 MTHFR
13 craniofacial MP:0005382 10.14 ABL1 ARID5B KMT2A MDM2 PBX1 PTPN11
14 nervous system MP:0003631 10.11 ABL1 BCR CDKN2A KMT2A MDM2 MTHFR
15 limbs/digits/tail MP:0005371 10.1 ARID5B KMT2A MDM2 MTHFR PBX1 PTPN11
16 neoplasm MP:0002006 10.1 CDKN2A ETV6 KMT2A MDM2 MLLT1 MLLT3
17 muscle MP:0005369 10.09 ABL1 ARID5B CDKN2A DHFR KMT2A MDM2
18 no phenotypic analysis MP:0003012 10.06 CDKN2A CYP1A1 ETV6 KMT2A MDM2 MLLT3
19 normal MP:0002873 10.03 ABL1 BCR CYP1A1 ETV6 KMT2A MDM2
20 renal/urinary system MP:0005367 9.81 ARID5B BCR KMT2A MDM2 MLLT1 PBX1
21 reproductive system MP:0005389 9.65 ARID5B CDKN2A KMT2A MDM2 MTHFR PBX1
22 skeleton MP:0005390 9.36 ABL1 ARID5B CDKN2A KMT2A MDM2 MLLT3

Drugs & Therapeutics for Childhood Leukemia

Drugs for Childhood Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorambucil Approved Phase 3 305-03-3 2708
2
alemtuzumab Approved, Investigational Phase 3 216503-57-0
3
Zoledronic Acid Approved Phase 3 118072-93-8 68740
4
Calcium carbonate Approved, Investigational Phase 3 471-34-1
5
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
7
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
8
Calcitriol Approved, Nutraceutical Phase 3 32222-06-3 134070 5280453
9 Antineoplastic Agents, Immunological Phase 3
10 Gastrointestinal Agents Phase 3
11 Hormones Phase 3
12 Micronutrients Phase 3
13 Vitamins Phase 3
14 Trace Elements Phase 3
15 Hydroxycholecalciferols Phase 3
16 Nutrients Phase 3
17 Diphosphonates Phase 3
18 Ergocalciferols Phase 3
19 Calciferol Phase 3
20 Vitamin D2 Phase 3
21 Anti-Ulcer Agents Phase 3
22 Antacids Phase 3
23
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
24
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
25
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
26 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
27
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
28
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
29
Blinatumomab Approved, Investigational Phase 2 853426-35-4
30
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
31
Pirarubicin Investigational Phase 2 72496-41-4
32
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
33 Methylprednisolone Acetate Phase 2
34 Antimitotic Agents Phase 1, Phase 2
35 Antibodies Phase 2
36 Antibodies, Bispecific Phase 2
37 Immunoglobulins Phase 2
38
Etoposide Approved Phase 1 33419-42-0 36462
39
Clofarabine Approved, Investigational Phase 1 123318-82-1 119182
40
Pravastatin Approved Phase 1 81093-37-0 54687
41
Methotrexate Approved Phase 1 1959-05-2, 59-05-2 126941
42
leucovorin Approved Phase 1 58-05-9 6006 143
43
Pegaspargase Approved, Investigational Phase 1 130167-69-0
44
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
45
Hydrocortisone acetate Approved, Vet_approved Phase 1 50-03-3
46
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
47
Hydrocortisone Approved, Vet_approved Phase 1 50-23-7 5754
48
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
49
Cytarabine Approved, Experimental, Investigational Phase 1 147-94-4, 65-46-3 6253
50
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Thiopurine Induced Pancreatitis in IBD Patients Withdrawn NCT02281799 Phase 4 Azathioprine
2 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
3 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
4 Analysis of Outcome of Bisphosphonate Use in Children With ALL- "Case Controlled Study" Completed NCT01656512 Phase 3 zolendronic acid;calcium & vitamin D
5 Diminished Bone Mineral Density in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Severity-Adapted Clinical Trial Completed NCT00186901 Phase 3 Calcium carbonate (Tums), vitamin D
6 Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients With BCR-ABL-Negative Acute Lymphoblastic Leukemia Unknown status NCT00131053 Phase 2 Methotrexate;Prednisolone;Dexamethasone;Vincristine;Pirarubicin;Cyclophosphamide;L-asparaginase;Cytarabine;Hydrocortisone;Mercaptopurine
7 Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE®) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia Completed NCT00560794 Phase 2
8 A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia Completed NCT00440726 Phase 1, Phase 2 bortezomib (Velcade);dexamethasone;PEG-asparaginase;doxorubicin;cytarabine;methotrexate;vincristine
9 A Phase I Trial of Bendamustine in Combination With Clofarabine and Etoposide in Pediatric Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01900509 Phase 1 Bendamustine;Clofarabine;Etoposide;Etoposide phosphate;Dexamethasone
10 Pilot Study to Evaluate the Tolerability of Velcade (Bortezomib) and Pravastatin for the Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children Active, not recruiting NCT02484261 Phase 1 Bortezomib;Pravastatin
11 Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML. Active, not recruiting NCT02091245 Phase 1 KPT-330
12 A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL) Terminated NCT00439296 Phase 1 ABT-751;dexamethasone;PEG-asparaginase;doxorubicin;cytarabine;methotrexate;cyclophosphamide;6-thioguanine
13 A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Terminated NCT02676323 Phase 1 Panobinostat;Fludarabine;Cytarabine;Intrathecal Triples;Leucovorin
14 Prevalence of Psychocognitive Impairments in Adolescents Surviving Childhood Leukemia : LEA-PsyCog Unknown status NCT01741662
15 The Metabolic Syndrome Among Childhood Acute Leukemia Survivors: Physiopathological Analysis Unknown status NCT02696304
16 Implementation of Innovative Techniques in Routine Diagnosis of Childhood Acute Leukemia: Analysis of Genome and Transcriptome by Micro-array Unknown status NCT02038361
17 Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study Unknown status NCT02644044 Early Phase 1 Intrathecal methotrexate
18 INTHEMO: Occupational Integration of Adults With Severe Haemophilia in France: a Study Based on the FranceCoag Cohort Unknown status NCT03301376
19 Phenotypic and Genotypic Associations With Symptom Clusters During Childhood Leukemia Treatment Completed NCT01708421
20 A Case-Control Study of Pesticides and Childhood Leukemia Completed NCT00342888
21 Case-Control Study of Urban Environmental Effects on Childhood Leukemia and Brain Cancer Completed NCT00505141
22 Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome Completed NCT02859389
23 Metabolic Syndrome Following Transplant for Leukemia Completed NCT00920842
24 Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure Completed NCT00015587
25 Incidence of Osteoporosis in Children With Acute Lymphoblastic Leukemia Undergoing Therapy Completed NCT00330538
26 Role of Pharmacogenetic and Psychological Factors in Methotrexate Tolerance: Studies in Children With Chronic Arthritis and Children With Leukemia Completed NCT02528435
27 Post-marketing Surveillance Study of the Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06 Completed NCT01025804
28 PACE-CALL: A Weight Control Intervention for Survivors of Childhood Leukemia Completed NCT01171599
29 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS) Completed NCT01663129
30 Aerobic and Strengthening Exercise for Acute Leukemia Completed NCT00766311
31 Influence on Hemostasis During Prolonged Asparaginase Treatment in Childhood and Adolescent ALL Recruiting NCT01094392
32 Lymphoproliferative Disorders During the Treatment of Childhood Acute Lymphoblastic Leukemia/Lymphoma Recruiting NCT04055558
33 INTERNATIONAL STUDY of Chronic Myeloid Leukaemia (CML) Treatment and Outcomes in Children and Adolescents Recruiting NCT01281735
34 N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors Active, not recruiting NCT01913093
35 Exercise and QUality Diet After Leukemia: The EQUAL Study Active, not recruiting NCT02244411
36 Early Life Exposures in Agriculture Active, not recruiting NCT02743481
37 Hematopoietic Stem Cell Transplantation and Childhood Leukemia: Quality of Life in SIbling DONors, Years After the Donation Not yet recruiting NCT03659071
38 Effects of Methylphenidate on Neuropsychological Functioning in Children With Attention Deficits Secondary to Childhood Cancer Terminated NCT01100658 Methylphenidate;Placebo
39 Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor Withdrawn NCT02000986

Search NIH Clinical Center for Childhood Leukemia

Genetic Tests for Childhood Leukemia

Anatomical Context for Childhood Leukemia

MalaCards organs/tissues related to Childhood Leukemia:

40
Myeloid, Bone, Bone Marrow, Brain, B Cells, T Cells, Lymph Node

Publications for Childhood Leukemia

Articles related to Childhood Leukemia:

(show top 50) (show all 2122)
# Title Authors PMID Year
1
Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. 42
31688884 2019
2
Case 34-2019: A 16-Year-Old Boy with Jaundice. 42
31665582 2019
3
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. 42
31477906 2019
4
Advanced glycation end products and chronic inflammation in adult survivors of childhood leukemia treated with hematopoietic stem cell transplantation. 61
31820553 2020
5
The future of cellular immunotherapy for childhood leukemia. 61
31851053 2020
6
Parental occupational exposure to pesticides, animals and organic dust and risk of childhood leukemia and central nervous system tumors: Findings from the International Childhood Cancer Cohort Consortium (I4C). 61
31054169 2020
7
Behavioral outcome among survivors of childhood brain tumor: a case control study. 61
32020861 2020
8
Effect of chemical modification with carboxymethyl dextran on kinetic and structural properties of L-asparaginase. 61
31821805 2020
9
Parental tobacco smoking and risk of childhood leukemia in Costa Rica: A population-based case-control study. 61
31655332 2020
10
Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia. 61
31556233 2020
11
Functional characterization of NK cells in Mexican pediatric patients with acute lymphoblastic leukemia: Report from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia. 61
31951638 2020
12
Untargeted adductomics of newborn dried blood spots identifies modifications to human serum albumin associated with childhood leukemia. 61
31760269 2020
13
Infections as a potential long-term risk following childhood leukemia. 61
31945656 2020
14
Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone health. 61
31536650 2020
15
The Impact of the Low Frequency of the Electromagnetic Field on Human. 61
31376139 2020
16
50 Years Ago in TheJournal ofPediatrics: Maintenance Therapy in Acute Childhood Leukemia. 61
31843123 2020
17
Space-time clustering of childhood leukemia in Colombia: a nationwide study. 61
31959128 2020
18
Early Recovery of Height Velocity in Prepubertal Children With Acute Lymphoblastic Leukemia Treated by a Short Intensive Phase Without Cranial Radiation Therapy. 61
31842181 2019
19
PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center. 61
31807902 2019
20
Early immune stimulation and childhood acute lymphoblastic leukemia in Costa Rica: A comparison of statistical approaches. 61
31911233 2019
21
Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort. 61
30639117 2019
22
Maternal Infection in Pregnancy and Childhood Leukemia: A Systematic Review and Meta-analysis. 61
31810630 2019
23
KCTD15 is overexpressed in human childhood B-cell acute lymphoid leukemia. 61
31882877 2019
24
Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan. 61
31559563 2019
25
Childhood leukemia could be a target for immunotherapy. 61
31792938 2019
26
Pathological and therapeutic aspects of matrix metalloproteinases: implications in childhood leukemia. 61
31802358 2019
27
Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia. 61
31885080 2019
28
Extremely low frequency electromagnetic fields and cancer: How source of funding affects results. 61
31476684 2019
29
Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. 61
31763683 2019
30
Improving classification accuracy of cancer types using parallel hybrid feature selection on microarray gene expression data. 61
31429008 2019
31
Microwaves from mobile phone induce reactive oxygen species but not DNA damage, preleukemic fusion genes and apoptosis in hematopoietic stem/progenitor cells. 61
31700008 2019
32
Highly sensitive chimerism detection in blood is associated with increased risk of relapse after allogeneic hematopoietic cell transplantation in childhood leukemia. 61
31313439 2019
33
Childhood leukemia in Ukraine after the Chornobyl accident. 61
31375997 2019
34
The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study. 61
31530240 2019
35
[Body composition evaluation by anthropometry and bioelectrical impedance analysis in childhood acute leukemia survivors]. 61
31755281 2019
36
Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. 61
31102422 2019
37
Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. 61
31264788 2019
38
Childhood leukemia survivors exhibit deficiencies in sensory and cognitive processes, as reflected by event-related brain potentials after completion of curative chemotherapy: A preliminary investigation. 61
31156064 2019
39
Cancer Stem Cells in the Development of Novel Therapeutics for Refractory Pediatric Leukemia. 61
31364487 2019
40
Coffee and tea consumption during pregnancy and risk of childhood acute myeloid leukemia: A Childhood Leukemia International Consortium (CLIC) study. 61
31416015 2019
41
Generation of a human induced pluripotent stem cell line, IMSUTi002-A-1, harboring the leukemia-specific fusion gene ETV6-RUNX1. 61
31476588 2019
42
Cardiovascular Testing Detects Underlying Dysfunction in Childhood Leukemia Survivors. 61
31652239 2019
43
Maternal diabetes and risk of childhood cancer in the offspring. 61
31658368 2019
44
Parental occupational exposure to low-frequency magnetic fields and risk of leukaemia in the offspring: findings from the Childhood Leukaemia International Consortium (CLIC). 61
31358566 2019
45
Small interfering RNA targeting of peroxiredoxinⅡ gene enhances formaldehyde-induced toxicity in bone marrow cells isolated from BALB/c mice. 61
31176251 2019
46
Influence of Inflammatory and Oxidative Stress Pathways on Longitudinal Symptom Experiences in Children With Leukemia. 61
31315444 2019
47
Long-Term Risk of Infections After Treatment of Childhood Leukemia: A Population-Based Cohort Study Using Administrative Health Data. 61
31393747 2019
48
Long-Term Risk of Hospitalization Among Five-Year Survivors of Childhood Leukemia in the Nordic Countries. 61
30753563 2019
49
Risk of selected childhood cancers and parental employment in painting and printing industries: A register-based case‒control study in Denmark 1968-2015. 61
30838423 2019
50
Childhood Leukemia, Late Effects, and a Person-centric Model of Follow-up. 61
30753660 2019

Variations for Childhood Leukemia

Expression for Childhood Leukemia

Search GEO for disease gene expression data for Childhood Leukemia.

Pathways for Childhood Leukemia

Pathways related to Childhood Leukemia according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1 12.71 TP53 RUNX1 MDM2 CDKN2A BCR ABL1
2
Show member pathways
12.66 TP53 RUNX1 PTPN11 MDM2 CDKN2A BCR
3
Show member pathways
12.44 TYMS TP53 MDM2 DHFR CDKN2A
4
Show member pathways
12.28 TP53 MDM2 CDKN2A ABL1
5 12.26 TP53 MDM2 CDKN2A ABL1
6
Show member pathways
12.2 TP53 SLC19A1 MTHFR DHFR
7 11.84 TP53 MDM2 CDKN2A ABL1
8 11.8 TP53 TCF3 MDM2 CDKN2A
9 11.76 TP53 MDM2 KMT2A CDKN2A
10
Show member pathways
11.73 TP53 MDM2 ABL1
11 11.7 TP53 PBX1 MDM2
12
Show member pathways
11.63 TP53 MDM2 CDKN2A
13 11.62 TP53 MDM2 CDKN2A
14 11.62 TP53 MDM2 CDKN2A
15 11.6 TYMS TP53 MDM2 DHFR ABL1
16
Show member pathways
11.58 TYMS TP53 MTHFR DHFR
17 11.55 TP53 TCF3 RUNX1 PBX1 MLLT3 MLLT1
18 11.5 TP53 MDM2 ABL1
19 11.46 TP53 MDM2 CDKN2A
20
Show member pathways
11.43 CYP1A1 BCR ABL1
21 11.18 TP53 MDM2 CDKN2A
22 11.11 TYMS SLC19A1 MTHFR DHFR
23
Show member pathways
10.8 TP53 MDM2 CDKN2A ABL1
24 10.6 TP53 MDM2 CDKN2A ABL1

GO Terms for Childhood Leukemia

Cellular components related to Childhood Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.03 TYMS TP53 TFPT TCF3 RUNX1 PTPN11
2 cytosol GO:0005829 9.8 TYMS TP53 RUNX1 PTPN11 MTHFR MLLT3
3 nucleolus GO:0005730 9.73 TYMS TP53 MDM2 ETV6 CDKN2A ABL1
4 nucleoplasm GO:0005654 9.44 TP53 TFPT TCF3 RUNX1 PTPN11 PBX1

Biological processes related to Childhood Leukemia according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.05 TP53 TCF3 RUNX1 MDM2 ETV6 ARID5B
2 positive regulation of transcription, DNA-templated GO:0045893 9.97 TP53 TCF3 RUNX1 MLLT3 KMT2A CDKN2A
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 TP53 TCF3 RUNX1 PBX1 KMT2A ETV6
4 response to drug GO:0042493 9.88 TYMS TP53 MTHFR MDM2 CYP1A1
5 regulation of transcription, DNA-templated GO:0006355 9.85 TP53 TCF3 RUNX1 PBX1 MLLT3 MLLT1
6 response to toxic substance GO:0009636 9.81 TYMS MDM2 CYP1A1
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.79 TP53 PTPN11 ABL1
8 multicellular organism growth GO:0035264 9.77 TP53 PTPN11 ARID5B
9 response to hyperoxia GO:0055093 9.64 TP53 CYP1A1
10 hematopoietic stem cell proliferation GO:0071425 9.63 RUNX1 ETV6
11 cardiac septum morphogenesis GO:0060411 9.62 TP53 MDM2
12 regulation of cellular senescence GO:2000772 9.61 TP53 ABL1
13 replicative senescence GO:0090399 9.61 TP53 CDKN2A
14 positive regulation of mitotic cell cycle GO:0045931 9.61 PTPN11 MDM2 ABL1
15 amyloid fibril formation GO:1990000 9.59 MDM2 CDKN2A
16 tetrahydrofolate interconversion GO:0035999 9.58 TYMS MTHFR
17 response to antibiotic GO:0046677 9.58 TP53 MDM2 CYP1A1
18 positive regulation of Wnt signaling pathway, planar cell polarity pathway GO:2000096 9.57 MLLT3 ABL1
19 negative regulation of ubiquitin-protein transferase activity GO:0051444 9.56 CDKN2A ABL1
20 regulation of hematopoietic stem cell differentiation GO:1902036 9.56 TCF3 RUNX1 KMT2A ABL1
21 Bergmann glial cell differentiation GO:0060020 9.55 PTPN11 ABL1
22 response to folic acid GO:0051593 9.54 TYMS MTHFR
23 cellular response to UV-C GO:0071494 9.52 TP53 MDM2
24 B cell lineage commitment GO:0002326 9.51 TP53 TCF3
25 folic acid metabolic process GO:0046655 9.5 SLC19A1 MTHFR DHFR
26 cellular response to actinomycin D GO:0072717 9.46 TP53 MDM2
27 tetrahydrofolate metabolic process GO:0046653 9.13 TYMS MTHFR DHFR
28 platelet-derived growth factor receptor signaling pathway GO:0048008 8.92 PTPN11 BCR ARID5B ABL1

Molecular functions related to Childhood Leukemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.97 TP53 TCF3 RUNX1 PBX1 KMT2A ETV6
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.77 TP53 TCF3 RUNX1 PBX1 ETV6
3 protein domain specific binding GO:0019904 9.76 PTPN11 MDM2 ETV6 ABL1
4 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.76 TP53 TCF3 RUNX1 PBX1 MLLT3 MLLT1
5 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.72 TP53 RUNX1 PBX1 ETV6 ARID5B
6 transcription regulatory region DNA binding GO:0044212 9.71 TP53 RUNX1 KMT2A ARID5B
7 DNA binding GO:0003677 9.7 TP53 TFPT TCF3 RUNX1 PBX1 MLLT1
8 translation repressor activity, mRNA regulatory element binding GO:0000900 9.48 TYMS DHFR
9 sequence-specific mRNA binding GO:1990825 9.43 TYMS DHFR
10 disordered domain specific binding GO:0097718 9.43 TP53 MDM2 CDKN2A
11 folic acid binding GO:0005542 8.8 TYMS SLC19A1 DHFR

Sources for Childhood Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....